Celecoxib Improves DFS, OS in ctDNA-Positive Colon Cancer
Celecoxib plus chemo can improve outcomes over placebo plus chemo in patients with colon cancer who have ctDNA-positive plasma after surgery.
Related Articles
Continuous Synthetic Hypericin Generates Responses in Early-Stage Cutaneous T-Cell Lymphoma
Treatment with synthetic hypericin for up to 12 months produced responses in early-stage cutaneous T-cell lymphoma.
Study identifies benefits, risks linked to popular weight-loss drugs | WashU Medicine
GLP-1 medications tied to decreased risk of dementia, addiction; increased risk of kidney, pancreas and gastrointestinal problems
Dr Fenske on ASCT Outcomes in MCL After First MRD-Negative CR
Timothy S. Fenske, MD, MS, shares outcomes from the phase 3 ECOG-ACRIN EA4151 trial of patients with mantle cell lymphoma after first MRD-negative CR.
Dr Wang on Ziftomenib Plus Intensive Induction in Newly Diagnosed, NPM1+ or KMT2A+ AML
Eunice S. Wang, MD, on ziftomenib plus intensive induction in newly diagnosed, NPM1-mutated or KMT2A-rearranged acute myeloid leukemia.
Incidence of Immune-Related Adverse Events With GI Cancers Relatively Low – Oncology Nurse Advisor
Researchers investigated immune-related adverse effects and characteristics that may predict their incidence in patients receiving ICIs for gastrointestinal cancers.
Genetic Testing Considerations and Questions Persist Surrounding Tumor-Agnostic Approvals
Pedro Barata, MD, details factors affecting treatment selection with biomarker-based approvals and highlights questions regarding genetic testing.
Real-World (RW) Observations from CAR T in R/R Myeloma
The panelist discusses how real-world evidence for CAR T in relapsed/refractory multiple myeloma shows promising efficacy but with some differences from clinical trials. Ide-cel demonstrates…
JNCCN 360 – CLL/MCL – BRUIN CLL-321 Trial: Update on Pirtobrutinib for BTK Inhibitor–Pretreated CLL or SLL
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Waldenström Macroglobulinemia: Results From the Phase 1 CaDAnCe-101 Study
Dr. John F. Seymour presents preliminary results from the Phase 1 CaDAnCe-101 study, highlighting the efficacy and safety of the BTK degrader BGB-16673 in relapsed…